Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

George Church, Wyss scientists and Northpond challenge conventional RNA manufacturing with new biotech

3 years ago

Solid Bio gets a new CEO, $75M cash and drops lead drug as big investors jury-rig a merger deal

3 years ago

BioMarin returns to FDA with a new pitch for hemophilia gene therapy — and a promise to get to the bottom of durability

3 years ago

FDA's advanced therapies office provides more clarity on gene therapy CMC considerations

3 years ago

Cell and gene therapies from academia: EMA to help 5 projects going after unmet clinical needs

3 years ago

Real-time reviews for cell and gene therapies? Pfizer to FDA: Yes, please

3 years ago

Now playing catch-up to bluebird, Vertex and CRISPR send in their pitch for blood disorder cell therapy

3 years ago

ArsenalBio lands $70M cash deal with cancer giant Genentech to develop cell therapy

3 years ago

Overworked and ready for expansion: FDA's cell and gene therapy office preps to add about 100 new positions

3 years ago

Armed with cash, Belgian iPSC player makes a play for Celyad’s cell therapy manufacturing site

3 years ago

Are $3M gene therapies the new normal? Experts say bluebird will be a test case for a market ready for prime time

3 years ago

Four years in the making, AbbVie and Calibr provide first look into ‘switchable’ CAR-T program

3 years ago

Carisma's CAR-M steals spotlight among 42 bidders to reverse merge with Sesen Bio

3 years ago

New patent on the prime editing of DNA awarded to Broad Institute's David Liu

3 years ago

TCR upstart gets fresh funding as it looks to charge toward the clinic

3 years ago

Renovacor ships its cardiac gene therapy to Rocket in $53M all-stock deal

3 years ago

Bluebird lands another rare disease gene therapy OK — but there are a few caveats to note

3 years ago

Fujifilm Diosynth breaks ground on a $1.6B expansion project in Denmark

3 years ago

Backed by five pharma giants and a crew of Penn superstars, a startup uses mRNA to create in vivo CAR-T — with a pro at the helm

3 years ago

‘Difficult to go public with’: SparingVision turns to existing backers to fund its first two ocular gene therapy trials

3 years ago

Rubius resorts to layoffs and abandons its lead programs as its survival strategy

3 years ago

BioMarin says PhIII gene therapy study participant's cancer is unrelated to therapy

3 years ago

#ESMO22: Adaptimmune touts new PhI data for its cell therapy treatment

3 years ago

Deerfield backs a Penn spinout aiming to shake up Parkinson's treatments using stem cells, brain surgery

3 years ago

First page Previous page 25 26 272829 30 31 Next page Last page